Baxter International

Last Updated:
In the Matter of Baxter International, a corporation
FTC Matter/File Number:

9710002

Docket Number:

C-3726

Enforcement Type:

Part 2 Consents

Case Summary

Consent order requires divestiture of Baxter's Autoplex product line of Factor VIII inhibitors used in the treatment for hemophilia and the licensing of Immuno International AG's fibrin sealant, a biologic product in development to be used to control bleeding in surgical procedures. According to the complaint issued with the final order, the acquisition of Immuno International would tend to create a monopoly and increase Baxter's ability to unilaterally raise prices in the market for the research, manufacture and sale of biologic products derived from human blood plasma.

Case Timeline